Faron Pharmaceuticals Oy (LSE:FARN) Operating Cash Flow per Share : £0.00 (TTM As of Dec. 2023)

View and export this data going back to 2015. Start your Free Trial

What is Faron Pharmaceuticals Oy Operating Cash Flow per Share?

Faron Pharmaceuticals Oy's operating cash flow per share for the six months ended in Dec. 2023 was £0.00. Faron Pharmaceuticals Oy's operating cash flow per share for the trailing twelve months (TTM) ended in Dec. 2023 was £0.00.

During the past 3 years, the average Operating Cash Flow per Share Growth Rate was 3.10% per year. During the past 5 years, the average Operating Cash Flow per Share Growth Rate was 6.10% per year. During the past 10 years, the average Operating Cash Flow per Share Growth Rate was -26.50% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the OCF Growth Rate using Operating Cash Flow per Share data.

The historical rank and industry rank for Faron Pharmaceuticals Oy's Operating Cash Flow per Share or its related term are showing as below:

LSE:FARN' s 3-Year OCF Growth Rate Range Over the Past 10 Years
Min: -252.8 Med: -11 Max: 15.8
Current: 3.1

During the past 12 years, Faron Pharmaceuticals Oy's highest 3-Year average Operating Cash Flow per Share Growth Rate was 15.80% per year. The lowest was -252.80% per year. And the median was -11.00% per year.

LSE:FARN's 3-Year OCF Growth Rate is ranked worse than
50.45% of 1233 companies
in the Biotechnology industry
Industry Median: 3.3 vs LSE:FARN: 3.10

Faron Pharmaceuticals Oy Operating Cash Flow per Share Historical Data

The historical data trend for Faron Pharmaceuticals Oy's Operating Cash Flow per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Faron Pharmaceuticals Oy Operating Cash Flow per Share Chart

Faron Pharmaceuticals Oy Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Operating Cash Flow per Share

Get a 7-Day Free Trial

-0.22

-0.29

-0.31

-0.30

-0.26

Faron Pharmaceuticals Oy Semi-Annual Data
	Dec13	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Operating Cash Flow per Share	Get a 7-Day Free Trial															-0.15	-0.15	-	-	-

Competitive Comparison of Faron Pharmaceuticals Oy's Operating Cash Flow per Share

For the Biotechnology subindustry, Faron Pharmaceuticals Oy's Price-to-Operating-Cash-Flow, along with its competitors' market caps and Price-to-Operating-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Faron Pharmaceuticals Oy's Price-to-Operating-Cash-Flow Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Faron Pharmaceuticals Oy's Price-to-Operating-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Faron Pharmaceuticals Oy's Price-to-Operating-Cash-Flow falls into.

Faron Pharmaceuticals Oy Operating Cash Flow per Share Calculation

Operating Cash Flow per Share is the amount of Cash Flow from Operations per outstanding share of the company's stock.

Faron Pharmaceuticals Oy's Operating Cash Flow per Share for the fiscal year that ended in Dec. 2023 is calculated as

Operating Cash Flow per Share (A: Dec. 2023 )	=	Cash Flow from Operations (A: Dec. 2023 )	/	Shares Outstanding (Diluted Average) (A: Dec. 2023 )
	=	-20.509	/	78.307
	=	-0.26

Faron Pharmaceuticals Oy's Operating Cash Flow per Share for the quarter that ended in Dec. 2023 is calculated as

Operating Cash Flow per Share (Q: Dec. 2023 )	=	Cash Flow from Operations (Q: Dec. 2023 )	/	Shares Outstanding (Diluted Average) (Q: Dec. 2023 )
	=	0	/	80.799
	=	0.00

Operating Cash Flow per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was £0.00

Faron Pharmaceuticals Oy Operating Cash Flow per Share Related Terms

Thank you for viewing the detailed overview of Faron Pharmaceuticals Oy's Operating Cash Flow per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Faron Pharmaceuticals Oy (LSE:FARN) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Faron Pharmaceuticals Oy (LSE:FARN) » Definitions » Operating Cash Flow per Share

Comparable Companies

Traded in Other Exchanges

FARON:Finland 4FR:Germany

Address

Joukahaisenkatu 6 B, Turku, FIN, 20520

Website

https://www.faron.com

Faron Pharmaceuticals Oy is a clinical-stage biopharmaceutical company developing novel treatments for medical conditions with unmet needs. The company has a pipeline based on the receptors involved in the regulation of immune response in oncology and organ damage. Clevegen (bexmarilimab), its investigative precision immunotherapy in phase I/II development as a novel macrophage checkpoint immunotherapy for patients with untreatable solid tumours, is a novel anti-Clever-1 antibody with the ability to switch immune suppression to immune activation. Traumakine, the company's investigational intravenous interferon beta-1a is an anti-viral and anti-inflammatory agent, being tested in several Phase III studies around the world against COVID-19.

Faron Pharmaceuticals Oy (LSE:FARN) Headlines

No Headlines